BMS-986218

Metastatic Liver Carcinoma

M.D. Anderson Cancer CenterPhase 1/2Dormant

D

30/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 15/ 100
Competitive Position: 95/ 100

Competitive context

112 Active assets in the Metastatic Liver Carcinoma cohort.

Asset / Sponsor	Phase	Rating
Bxcl501 Uppsala University Hospital	Phase 4	BBB
Inno-206 Shanghai Zhongshan Hospital	Phase 4	BB
Eloxatin Sun Yat-sen University	Phase 3	BB
Hepatitis B Virus Vaccine Eunice Dube	Phase 4	BB
Tranexamic Acid Konkuk University Medical Center	Phase 4	BB

View all 50 →

Same molecule, other indications

BMS-986218 is also rated in:

castration-resistant prostate carcinomaDormant

C

Indicative ·

33 / 100

adrenal gland cancerDormant

D

Indicative ·

30 / 100

Advanced Malignant Solid NeoplasmDormant

D

Indicative ·

30 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.